EP08.02-012. Real-world Analysis of the Efficacy and Safety of lorlatinib in Patients with ALK-Positive Non-small Cell Lung Cancer in Korea
Back to course
Pdf Summary
Asset Subtitle
Beung-chul AHN
Meta Tag
Speaker Beung-chul AHN
Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
Keywords
lorlatinib
ALK-positive non-small cell lung cancer
tyrosine kinase inhibitor
real-world data
Korea
progression-free survival
overall survival
objective response rate
adverse events
treatment history
Powered By